Fri, Nov 29, 2024
Volume 11, Issue 3 (May-Jun 2017)
mljgoums 2017, 11(3): 10-14 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zandi M, Ebrahimifard M, moradi A. Evaluation of miR-101 Level in Patients with Chronic Hepatitis B Virus Infection and Liver Cirrhosis. mljgoums 2017; 11 (3) :10-14
URL: http://mlj.goums.ac.ir/article-1-977-en.html
URL: http://mlj.goums.ac.ir/article-1-977-en.html
Evaluation of miR-101 Level in Patients with Chronic Hepatitis B Virus Infection and Liver Cirrhosis
1- Department of Biology, College of Sciences, Damghan branch, Islamic Azad University, Damghan, Iran
2- Departement of Microbiology. Golestan University of Medical Sciences, Gorgan, Iran ,abmoradi@gmail.com
2- Departement of Microbiology. Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (12191 Views)
ABSTRACT
Background and Objective: MiRNAs are small RNAs that are expressed in most eukaryotes, and can regulate gene expression by attaching to the 3’ end of target mRNA. MicroRNA-101 (miR-101) post-transcriptional regulation is important for host-virus interactions. In addition, miR-101 has a tumor suppressive role in liver cancer and metastasis, and induces apoptosis in tumor cells. We examined miR-101 expression in patients with chronic hepatitis B, hepatitis B virus (HBV)-associated cirrhosis and healthy individuals.
Methods: The study was performed on 108 whole blood samples (36 samples from each group) collected in EDTA tubes. RNA was extraction by RNX-plus kit according to the manufacturer’s protocol. Finally, miRNA expression was evaluated using relative real time PCR.
Results: A 2.4-fold increase was observed in miR-101 expression in patients with chronic hepatitis B, while there was a 3.5-fold increase in miR-101 expression in patients with HBV-associated cirrhosis compared with healthy controls (P=0.003). MiR-101 overexpression in patients with HBV-associated cirrhosis was more notable that in patients with chronic hepatitis B.
Conclusion: According to the results, evaluating miR-101 expression may predict disease progression from chronic hepatitis B to HBV-associated cirrhosis.
Keywords: MicroRNAs, Chronic Hepatitis B, Liver Cirrhosis, MiR-101.
Background and Objective: MiRNAs are small RNAs that are expressed in most eukaryotes, and can regulate gene expression by attaching to the 3’ end of target mRNA. MicroRNA-101 (miR-101) post-transcriptional regulation is important for host-virus interactions. In addition, miR-101 has a tumor suppressive role in liver cancer and metastasis, and induces apoptosis in tumor cells. We examined miR-101 expression in patients with chronic hepatitis B, hepatitis B virus (HBV)-associated cirrhosis and healthy individuals.
Methods: The study was performed on 108 whole blood samples (36 samples from each group) collected in EDTA tubes. RNA was extraction by RNX-plus kit according to the manufacturer’s protocol. Finally, miRNA expression was evaluated using relative real time PCR.
Results: A 2.4-fold increase was observed in miR-101 expression in patients with chronic hepatitis B, while there was a 3.5-fold increase in miR-101 expression in patients with HBV-associated cirrhosis compared with healthy controls (P=0.003). MiR-101 overexpression in patients with HBV-associated cirrhosis was more notable that in patients with chronic hepatitis B.
Conclusion: According to the results, evaluating miR-101 expression may predict disease progression from chronic hepatitis B to HBV-associated cirrhosis.
Keywords: MicroRNAs, Chronic Hepatitis B, Liver Cirrhosis, MiR-101.
Research Article: Original Paper |
Received: 2017/08/7 | Accepted: 2017/08/7 | Published: 2017/08/7 | ePublished: 2017/08/7
Received: 2017/08/7 | Accepted: 2017/08/7 | Published: 2017/08/7 | ePublished: 2017/08/7
References
1. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013; 21: 973-985. doi: 10.1038/mt.2013.31. [DOI:10.1038/mt.2013.31]
2. Jiang X, Kanda T, Wu Sh, Nakamura M, Miyamura T, Nakamoto Sh, et al. Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol. 2014; 20(23): 7197-7206. [DOI:10.3748/wjg.v20.i23.7197]
3. Zhang x, Hou J, MengjiLu. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet. 2013; 4: 202. doi: 10.3389/fgene.
4. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, at al. Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival. Clin Cancer Res. 2008; 14(2):419-27. doi: 10.1158/1078-0432.CCR-07-0523. [DOI:10.1158/1078-0432.CCR-07-0523]
5. Du Y, Han X, Pu R, Xie J, Zhang Y, Cao G. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Front Med. 2014; 8(2): 217-26. doi: 10.1007/s11684-014-0326-2. [DOI:10.1007/s11684-014-0326-2]
6. Waidmann O, Koberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis. PLoS One. 2012; 7(9): e45652. doi: 10.1371/journal.pone.0045652. [DOI:10.1371/journal.pone.0045652]
7. Mizukoshi E, Sidney J, Livingston B, Ghany G, Hoofnagle JH, Sette A, et al. Cellular Immune Responses to the Hepatitis B Virus. J Immunol 2004; 173(9): 5863-71. [DOI:10.4049/jimmunol.173.9.5863]
8. Bendinelli M, Pistello M, Freer G, Vatteroni M, Maggi F: Viral hepatitis. In: Rose NR, Hamilton RG, Detrick B: Manual of clinical laboratory immunology. Washington, D.C, ASM Press, 696-717, 2002.
9. Thomas F Baumert, Robert Thimme, Fritz von Weizsacker . Pathogenesis of hepatitis B virus infection. World J Gastroenterol. 2007; 13(1): 82-90. doi: 10.1016/j.patbio.2009.11.001. [DOI:10.1016/j.patbio.2009.11.001]
10. Hanazaki K. Antiviral Therapy for Chronic Hepatitis B: A Review. Curr Drug Targets Inflamm Allergy. 2004; 3(1): 63-70. [DOI:10.2174/1568010043483908]
11. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107(7): 823-6. [DOI:10.1016/S0092-8674(01)00616-X]
12. Muriel G, Emmanuel J, Arnold M, Stanislas L, Alexandra H. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008; 48(4): 648-56. doi: 10.1016/j.jhep.2008.01.019. [DOI:10.1016/j.jhep.2008.01.019]
13. Cuellar TL, McManus MT. MicroRNAs and endocrine biology. J Endocrinol. 2005; 187(3): 327-32. [DOI:10.1677/joe.1.06426]
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-97. [DOI:10.1016/S0092-8674(04)00045-5]
15. Feng B , Wei L, Chen M, Wang L. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B. Microbiological Research. 2008; 163(4): 487-492. [DOI:10.1016/j.micres.2006.11.004]
16. Wei YF, Cui GY, Ye P, Chen JN, Diao HY. MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol. 2013; 19(30): 4867-4876. doi: 10.3748/wjg.v19.i30.4867. [DOI:10.3748/wjg.v19.i30.4867]
17. Jules L. Dienstag, M.D.; Abdul Alaama, M.D.; James W. Mosley, M.D.; Allan G. Redeker, M.D.; Robert H. Purcell, M.D. Etiology of Sporadic Hepatitis B Surface Antigen-Negative Hepatitis. Published: Ann Intern Med. 1977;87(1):1-6. DOI: 10.7326/0003-4819-87-1-1. [DOI:10.7326/0003-4819-87-1-1]
18. Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal. 2013; 25(2): 439-46. doi: 10.1016/j.cellsig.2012.10.013. [DOI:10.1016/j.cellsig.2012.10.013]
19. Xie Y, Yao Q , Butt AM, Guo J, Tian Zh, Bao X, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014; 15(9): 1248-55. doi: 10.4161/cbt.29688. [DOI:10.4161/cbt.29688]
20. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322: 1695-9. [DOI:10.1126/science.1165395]
21. Qazi AM, Gruzdyn O, Semaan A, Seward Sh, Chamala S, Dhulipala V, et al. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery. 2012; 152(4): 704-11. doi: 10.1016/j.surg.2012.07.020. [DOI:10.1016/j.surg.2012.07.020]
22. Bae JS, Kim JK, Pasaje CF A, Cheong HS, Lee TH, Koh IS, et al. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012; 44(10): 849-54. doi: 10.1016/j.dld.2012.04.021. [DOI:10.1016/j.dld.2012.04.021]
23. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010; 46(12): 2295-303. [DOI:10.1016/j.ejca.2010.05.012]
24. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, et al. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett. 2013; 341(2): 240-7. [DOI:10.1016/j.canlet.2013.08.021]
25. Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, Wu Z. Circulating microRNA-101 as apotential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2013; 6(6):1811-1815.
26. Wei YF, Cui GY, Ye P, Chen JN, Diao HY. MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol 2013; 19(30): 4867-4876. [DOI:10.3748/wjg.v19.i30.4867]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.